Please login to the form below

Not currently logged in
Email:
Password:

Millennium submits new Velcade applications

Millennium has submitted applications to the US Food and Drug Administration seeking approval of two new indications for its injectable cancer drug Velcade

Millennium has submitted applications to the US Food and Drug Administration (FDA) seeking approval of two new indications for its injectable cancer drug Velcade (bortezomib).

The first application seeks approval of a subcutaneous route of administration for the drug, which is currently approved only as an intravenous therapy. The second seeks approval of Velcade in combination with rituximab for the treatment of relapsed follicular non-Hodgkin lymphoma (NHL).

Velcade, a proteasome inhibitor, was granted accelerated approval in the US in 2003 as a treatment for multiple myeloma. The drug was approved in the US in 2007 as a treatment for patients with mantle cell lymphoma, which is a sub-type of NHL, who have received at least one prior therapy.

The newly submitted supplemental new drug applications (sNDAs) were based on results from clinical trials that were presented at the American Society of Hematology (ASH) annual meeting in late 2010. The subcutaneous pivotal trial findings were also published in the online version of the Lancet Oncology earlier this month.

27th April 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...